Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Apixaban for Patients with Intrahepatic Non-Cirrhotic Portal Hypertension

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as intrahepatic non-cirrhotic portal hypertension (INCPH). This is a liver-related condition where there is high blood pressure in the portal vein system, which carries blood from the digestive organs to the liver, but it occurs without the presence of liver cirrhosis. The trial will evaluate the effects of a medication called apixaban, which is a blood thinner, to see if it can help prevent or reduce the formation of blood clots in the portal vein system. Participants in the study will receive either Eliquis 2.5 mg film-coated tablets, which contain apixaban, or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to assess the impact of taking apixaban over a period of 24 months on the development or worsening of blood clots in the portal vein system. This includes areas such as the splenic and mesenteric veins, as well as the main portal vein and its branches. The study will involve regular check-ups and imaging tests, such as CT scans, to monitor the condition of the veins and ensure the safety and well-being of the participants.

Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This approach helps to ensure that the results of the study are unbiased and reliable. The trial is expected to last for about two years, during which time participants will be closely monitored for any changes in their condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria, including age and medical condition. The condition being studied is intrahepatic non-cirrhotic portal hypertension.

    Participants must be between 18 and 90 years old. Women of childbearing age must use specific forms of contraception.

  2. Step 2

    Randomization and medication assignment

    Participants are randomly assigned to receive either the medication apixaban or a placebo. Apixaban is a film-coated tablet taken orally.

    The dosage for apixaban is 2.5 mg, taken twice daily.

  3. Step 3

    Treatment period

    The treatment period lasts for 24 months. During this time, participants continue to take their assigned medication as instructed.

    The main goal is to observe the effect of the medication on the occurrence or extension of thrombosis in the portal venous system.

  4. Step 4

    Monitoring and assessments

    Participants undergo regular monitoring, including CT scans, to assess any changes in the portal venous system.

    These assessments are conducted with a centralized imaging review to ensure accuracy and consistency.

  5. Step 5

    Completion of the study

    At the end of the 24-month period, the study concludes. The primary endpoint is the cumulative incidence of thrombosis occurrence or extension.

    Results are analyzed to determine the effectiveness of apixaban compared to the placebo.

Who can join the trial?

7 criteria

  • Patients must be between 18 and 90 years old.
  • Both men and women can participate.
  • Women who can have children must use birth control methods such as pills, an intrauterine device (IUD), or other mechanical methods.
  • Patients must have proper prevention measures against bleeding from varices, which are swollen veins, as recommended by the European Association for the Study of the Liver (EASL).
  • Patients must have **Intrahepatic Non-Cirrhotic Portal Hypertension (INCPH)**, which is a condition related to blood flow in the liver. This is determined by:
    • No cirrhosis (liver scarring) found in a liver biopsy, and at least one sign specific to portal hypertension.
    • No cirrhosis found in a liver biopsy, at least one sign not specific to portal hypertension, and at least one histological sign (tissue examination) for INCPH.
    • If no liver biopsy is available, two reliable liver stiffness measurements using a special scan called **Fibroscan** must be less than 10 kPa, along with at least one sign specific to portal hypertension.

Who cannot join the trial?

3 criteria

  • Patients with **intrahepatic non-cirrhotic portal hypertension** cannot participate. This is a condition where there is high blood pressure in the veins of the liver, but not due to liver scarring.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, meaning they might need special protection or care, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Apixaban is a medication used in this clinical trial to help prevent blood clots in patients with a specific liver condition called intrahepatic non-cirrhotic portal hypertension (INCPH). The trial aims to see if taking apixaban for 24 months can reduce the occurrence or worsening of blood clots in the veins around the liver, such as the splenic, mesenteric, and portal veins.

What is already known about the treatment

Apixaban – Apixaban is administered orally in tablet form, typically taken twice a day. It is currently being studied in clinical trials for its effects on intrahepatic non-cirrhotic portal hypertension, a condition affecting blood flow in the liver. The main therapeutic indication for apixaban in this trial is to prevent or reduce the formation of blood clots in the portal venous system. At the molecular level, apixaban works by inhibiting Factor Xa, an enzyme crucial for blood clotting, thereby reducing the risk of clot formation. It is classified as an anticoagulant, specifically a direct oral anticoagulant (DOAC).

Investigated diseases

Intrahepatic Non-Cirrhotic Portal Hypertension – This condition involves increased blood pressure in the portal vein system, which carries blood from the digestive organs to the liver, without the presence of liver cirrhosis. It can lead to the development of varices, which are enlarged veins that can cause complications if they rupture. The disease progresses as the pressure in the portal vein increases, potentially leading to the formation of blood clots in the portal venous system. Over time, this can result in the extension of thrombosis, affecting additional veins such as the splenic or mesenteric veins. The condition may cause symptoms like abdominal pain, swelling, and digestive issues due to impaired blood flow.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-514348-95-00Protocol codeP170916JEstimated enrolment166 patientsSponsorAssistance Publique Hopitaux De Paris

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).